Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Growth Rate of the Granulomatosis With Polyangiitis Treatment Market?
In recent years, the treatment market for granulomatosis with polyangiitis has shown considerable development. It is projected to expand from $2.36 billion in 2024 to $2.56 billion in 2025 with an annual compound growth rate (CAGR) of 8.2%. The remarkable growth observed in the historic period is associated with the increasing necessity for medicinal drugs, an increment in the number of clinical trials, higher demand for effective treatment approaches, a heightened focus on personalized medicine, and a rise in the detection rates of the disease.
What Growth Rate Is Forecasted for the Granulomatosis With Polyangiitis Treatment Market by 2029?
In the forthcoming years, it is projected that the market for granulomatosis with polyangiitis treatment will experience robust growth. The market size is set to expand to $3.47 billion in 2029, growing at a compound annual growth rate of 7.9%. Factors contributing to this growth during the forecast period include a surge in autoimmune diseases, a rise in granulomatosis instances, an increase in polyangiitis cases, and a boost in immunological disorders. Some of the predominant trends for the forecast period include strides in drug advancement, improvements in healthcare, progress in diagnostic procedures, enhancements in treatment options, and the growth of biologics and biosimilars.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21196&type=smp
Which Key Companies Are Shaping the Future of the Granulomatosis With Polyangiitis Treatment Market?
Major companies operating in the granulomatosis with polyangiitis treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Sanofi S.A., AstraZeneca plc, GlaxoSmithKline plc, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Vertex Pharmaceuticals Incorporated, Genentech Inc., Incyte Corporation, Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., ChemoCentryx Inc., Medac Pharma Inc., InflaRx GmbH
Which Factors Are Driving Demand in the Granulomatosis With Polyangiitis Treatment Industry?
The rise in autoimmune diseases, which occur when the body’s immune system mistakenly attacks its own healthy cells and tissues, is anticipated to spur the expansion of the granulomatosis with polyangiitis treatment market. The prevalence of these diseases is increasing due to factors like environmental triggers, such as infections, chemicals, or pollutants, and changes in lifestyle. Therapies like corticosteroids and cyclophosphamide, used in granulomatosis with polyangiitis treatment, can control inflammation and prevent organ damage, underscoring the importance of early intervention and personalized treatment for managing other autoimmune conditions with similar mechanisms. A report from the UK-based Office for National Statistics in June 2023 showed, for example, that the global population of people suffering from multiple sclerosis (an autoimmune disease) increased to 2.9 million in 2023 from 2.8 million in 2022. Thus, the escalating prevalence of autoimmune diseases is fuelling the expansion of granulomatosis with polyangiitis treatment market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=21196&type=smp
How Is the Granulomatosis With Polyangiitis Treatment Market Segmented by Several Divisions?
The granulomatosis with polyangiitis treatment market covered in this report is segmented –
1) By Drug Type: Steroids, Immunosuppressant, Other Drug Types
2) By Treatment Type: Immunosuppressants, Corticosteroids
3) By Route Of Administration: Oral, Intravenous
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
5) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Steroids: Prednisone, Methylprednisolone, Dexamethasone, Hydrocortisone
2) By Immunosuppressants: Cyclophosphamide, Methotrexate, Azathioprine, Mycophenolate mofetil, Rituximab
3) By Other Drug Types: Plasma Exchange Therapy, Intravenous Immunoglobulin (IVIG), Biologic Agents, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
What are the Emerging Market Trends Driving the Growth of the Granulomatosis With Polyangiitis Treatment Industry?
Key players in the granulomatosis with polyangiitis treatment market are concentrating on the creation of unique products such as oral corticosteroids. This move is aimed at providing more potent treatment solutions that not only handle the disorder more effectively but also reduce the potential long-term adverse effects of using steroids. Oral corticosteroids, a class of drugs known for their anti-inflammatory and immunosuppressive properties, are typically used for managing allergies, autoimmune diseases, and inflammatory conditions. For example, in October 2024, the UK’s pharmaceutical giant, AstraZeneca plc, announced that its product, Fasenra (bevacizumab), had gained approval in the European Union, an economic and political confederation of European countries. This approval was for the use of Fasenra as an added treatment for adult sufferers of relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA). This decision was backed by encouraging results from the MANDARA Phase III trial, which showcased Fasenra’s effectiveness in inducing remission and decreasing dependence on oral corticosteroids in EGPA patients.
Access The Full Report Here:
Which Regions Are Driving Growth in the Granulomatosis With Polyangiitis Treatment Market?
North America was the largest region in the granulomatosis with polyangiitis treatment market in 2024. The regions covered in the granulomatosis with polyangiitis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21196
This Report Delivers Insight On:
1. How big is the granulomatosis with polyangiitis treatment market, and how is it changing globally?
2. Who are the major companies in the granulomatosis with polyangiitis treatment market, and how are they performing?
3. What are the key opportunities and risks in the granulomatosis with polyangiitis treatment market right now?
4. Which products or customer segments are growing the most in the granulomatosis with polyangiitis treatment market?
5. What factors are helping or slowing down the growth of the granulomatosis with polyangiitis treatment market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model